High prevalence of local coronary arterial inflammation in clinically stable subjects after myocardial infarction: findings from the FORTIFY trial screenees

orticumab (BI 204) - Roche, Abcentra

T Villines1; C Farina2; W Lu2; A Gille2; K Melvin2; C Shirodaria3; C Antoniades4; J Nilsson5; P Libby6

May 11, 2026